A Phase 1 interventional study of LY4226695 and LY4226695 in Healthy, sponsored by Eli Lilly and Company. Recruiting at 2 sites in 2 countries. Open to participants aged 22 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-22.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
The main purpose of this study is to assess how well LY4226695 is tolerated and what side effects may occur in healthy participants. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. For each participant in Parts A \& D, the study will last about 64 days and will include a stay in the Clinical Research Unit (CRU) lasting at most 7 days. For each participant in Parts B \& C, the study will last about 92 days and will include 5 stays in the CRU with each visit lasting at most 7 days.
Part B Chinese participants:
Part C Japanese participants:
Exclusion Criteria:
Participants will receive LY4226695 or placebo administered subcutaneously (SC)
Drug: LY4226695 · Drug: Placebo
Participants will receive LY4226695 or placebo administered SC
Drug: LY4226695 · Drug: Placebo
Participants will receive LY4226695 or placebo administered SC
Drug: LY4226695 · Drug: Placebo
Participants will receive LY4226695 administered intravenously (IV)
Drug: LY4226695
Administered SC
Administered IV
Administered SC
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Time frame: Baseline through Day 57
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY4226695
Time frame: Baseline through Day 57
PK: Maximum Concentration (Cmax) of LY4226695
Time frame: Baseline through Day 57
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eli Lilly and Company